Literature DB >> 35907102

Long-term risk of adverse cardiovascular outcomes associated with cutaneous lupus erythematosus: a nationwide cohort study.

Abdulrahman N Shams-Eldin1, Adelina Yafasova1, Mikkel Faurschou2, Morten Schou3, Guoli Sun1, Gunnar H Gislason4,5, Christian Torp-Pedersen6,7,8, Emil L Fosbøl1, Lars Køber1, Jawad H Butt9.   

Abstract

BACKGROUND: Autoimmune diseases, including systemic lupus erythematosus, have been associated with a substantial risk of cardiovascular morbidity and mortality. However, data on the long-term risk of incident heart failure and other adverse cardiovascular outcomes among patients diagnosed with cutaneous lupus erythematosus (CLE) are limited.
METHODS: In this cohort study, all patients ≥ 18 years with newly diagnosed CLE between 1996 and 2018 were identified through Danish nationwide registries and matched 1:4 by age, sex, and comorbidity with individuals without CLE. Incident adverse cardiovascular outcomes, including heart failure, were compared between the matched groups, overall, and according to sex.
RESULTS: Of 2085 patients diagnosed with CLE, 2062 patients were matched with 8248 control subjects from the Danish background population (median age 50 years [25th-75th percentile: 37-62 years]; 22.3% men). The median follow-up was 6.2 years. The 10-year cumulative incidences and adjusted hazard ratios (HR) of outcomes were as follows: heart failure: 3.29% (95% CI, 2.42-4.36%) for CLE patients versus 2.59% (2.20-3.02%) for the background population, HR 1.67 (95% CI, 1.24-2.24); atrial fibrillation or flutter: 5.15% (3.99-6.52%) versus 3.84% (3.37-4.36%), HR 1.40 (1.09-1.80); the composite of ICD implantation, ventricular arrhythmia, or cardiac arrest: 0.72% (0.34-1.40%) versus 0.44% (0.29-0.64%), HR 1.71 (0.85-3.45); the composite of pacemaker implantation, atrioventricular block, or sinoatrial dysfunction: 0.91% (0.48-1.59%) versus 0.54% (0.37-0.76%), HR 1.32 (0.72-2.41); myocardial infarction: 3.05% (2.18-4.15%) versus 1.59% (1.29-1.93%), HR 2.15 (1.53-3.00); ischemic stroke: 3.25% (2.38-4.32%) versus 2.50% (2.13-2.93%), HR 1.56 (1.16-2.10); and venous thromboembolism: 2.74% (1.94-3.75%) versus 2.05% (1.71-2.44%), HR 1.60 (1.16-2.21). Sex did not modify the association between CLE and adverse cardiovascular outcomes (Pinteraction ≥ 0.12 for all outcomes).
CONCLUSIONS: Patients with CLE had a higher associated risk of adverse cardiovascular outcomes compared with the background population, irrespective of sex. Key Points • Findings: In this nationwide cohort study, including 2062 patients with cutaneous lupus erythematosus and 8248 matched controls, cutaneous lupus erythematosus was associated with an increased long-term risk of heart failure, cardiac arrhythmias, and thromboembolic events, irrespective of sex.
© 2022. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).

Entities:  

Keywords:  Cardiac arrhythmias; Cutaneous lupus erythematosus; Heart failure; Thromboembolism

Mesh:

Year:  2022        PMID: 35907102     DOI: 10.1007/s10067-022-06302-z

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   3.650


  32 in total

Review 1.  Type I Interferon as cardiovascular risk factor in systemic and cutaneous lupus erythematosus: A systematic review.

Authors:  Chiara Kirchler; Emma Husar-Memmer; Klemens Rappersberger; Kylie Thaler; Ruth Fritsch-Stork
Journal:  Autoimmun Rev       Date:  2021-03-17       Impact factor: 9.754

2.  Cutaneous lupus erythematosus and the risk of deep venous thrombosis and pulmonary embolism: A Danish nationwide cohort study.

Authors:  O Ahlehoff; J J Wu; J Raunsø; S L Kristensen; U Khalid; K Kofoed; G Gislason
Journal:  Lupus       Date:  2017-06-15       Impact factor: 2.911

Review 3.  Cutaneous lupus erythematosus: clinico-pathologic correlation.

Authors:  Raffaele Filotico; Valentina Mastrandrea
Journal:  G Ital Dermatol Venereol       Date:  2018-01-24       Impact factor: 2.011

Review 4.  Cutaneous lupus erythematosus and cardiovascular disease: current knowledge and insights into pathogenesis.

Authors:  Lisa N Guo; Vinod E Nambudiri
Journal:  Clin Rheumatol       Date:  2020-07-05       Impact factor: 2.980

5.  Cutaneous lupus erythematosus and systemic lupus erythematosus are associated with clinically significant cardiovascular risk: a Danish nationwide cohort study.

Authors:  J Halskou Hesselvig; O Ahlehoff; L Dreyer; G Gislason; K Kofoed
Journal:  Lupus       Date:  2016-05-27       Impact factor: 2.911

6.  Psoriasis and risk of heart failure: a nationwide cohort study.

Authors:  Usman Khalid; Ole Ahlehoff; Gunnar Hilmar Gislason; Søren Lund Kristensen; Lone Skov; Christian Torp-Pedersen; Peter Riis Hansen
Journal:  Eur J Heart Fail       Date:  2014-06-05       Impact factor: 15.534

Review 7.  Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications.

Authors:  Bryant R England; Geoffrey M Thiele; Daniel R Anderson; Ted R Mikuls
Journal:  BMJ       Date:  2018-04-23

Review 8.  Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies.

Authors:  Joerg Wenzel
Journal:  Nat Rev Rheumatol       Date:  2019-08-09       Impact factor: 20.543

9.  Clinical manifestations of cutaneous lupus erythematosus.

Authors:  Annegret Kuhn; Michael Sticherling; Gisela Bonsmann
Journal:  J Dtsch Dermatol Ges       Date:  2007-12       Impact factor: 5.584

10.  Disease activity in inflammatory bowel disease is associated with increased risk of myocardial infarction, stroke and cardiovascular death--a Danish nationwide cohort study.

Authors:  Søren Lund Kristensen; Ole Ahlehoff; Jesper Lindhardsen; Rune Erichsen; Gunnar Vagn Jensen; Christian Torp-Pedersen; Ole Haagen Nielsen; Gunnar Hilmar Gislason; Peter Riis Hansen
Journal:  PLoS One       Date:  2013-02-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.